Tumor immune microenvironment score predicts efficacy of immune checkpoint inhibitors-based regimens in advanced non-small cell lung cancer.

ABSTRACT:

Background

Immune checkpoint inhibitor (ICI)-based regimens have become the standard first-line treatment for advanced non-small cell lung cancer (NSCLC). However, response rates vary widely, emphasizing the need for a predictive model to optimize patient selection and improve treatment outcomes.

Methods

We retrospectively analyzed 96 treatment-naïve patients with advanced NSCLC who received first-line ICI-based regimens (anti-PD-1 ± platinum chemotherapy) at Hunan Cancer Hospital. Pre-treatment tumor biopsies underwent bulk RNA sequencing to identify differentially expressed genes associated with progression-free survival (PFS). A five-gene Cox proportional hazards model, the Prediction model of Immunotherapy Efficacy (PIE), was developed and validated in two independent co

SUBMITTER: Dai J 

PROVIDER: S-EPMC12699922 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature